Positive results for MS drug

Published: 2-Mar-2001


Elan and Biogen have announced positive results from two Phase II clinical studies on natalizumab (Antegren) in treating multiple sclerosis and Crohn's disease. The companies hope to start Phase III trials on the humanised monoclonal antibody this year.

See more

You may also like

Sustainability
Gerresheimer commissions photovoltaic system in Pfreimd

Gerresheimer commissions photovoltaic system in Pfreimd

Read more
Approximately 500,000 kWh of solar power annually from own rooftops | Expansion of the share of renewable energy at the site

Trending Articles

  1. Johnson & Johnson to spend up to $750m restructuring pharmaceutical supply chain The pharma giant is consolidating parts of its manufacturing network as it advances a $55bn US investment programme aimed at expanding domestic production of advanced medicines
  2. Sativex approved in Sweden For the treatment of spasticity due to multiple sclerosis
  3. Takara Bio extends biomanufacturing capabilities with custom enzyme manufacturing lab Its Gothenburg facility now has a manufacturing lab that can produce customised molecular biology products such as PCR and qPCR enzymes
  4. Leica Biosystems acquires StatLab to strengthen anatomic pathology and AI-enabled cancer diagnostics The deal adds StatLab's 50-year histology workflow portfolio to Leica Biosystems' computational pathology platform, supporting laboratory standardisation for AI-driven cancer diagnostics at scale
  5. Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones Piramal Pharma Limited (PPL) (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all

You may also like

Sustainability
Gerresheimer commissions photovoltaic system in Pfreimd

Gerresheimer commissions photovoltaic system in Pfreimd

Approximately 500,000 kWh of solar power annually from own rooftops | Expansion of the share of renewable energy at the site
Analysis
New chemisorption analyser redefines catalyst characterisation

New chemisorption analyser redefines catalyst characterisation

Anton Paar introduces the Autosorb 3300: Advanced flow chemisorption analysis with unprecedented ease of use and automation
Research & Development
Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal

Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal

Cambridge-based biotech Mission Therapeutics has divested its Phase II-ready USP30 inhibitor MTX652 to renal specialist Dimerix in a deal worth up to $292m, allowing the company to accelerate its Parkinson’s disease pipeline
Pharma 5.0
FPT launches MediSight AI framework to accelerate pharma digital transformation and regulatory compliance

FPT launches MediSight AI framework to accelerate pharma digital transformation and regulatory compliance

The new AI-powered platform combines autonomous digital workers, interoperable healthcare data and compliance tools to help pharmaceutical manufacturers, medical device companies and healthcare providers scale AI adoption
Regulatory
Early phase analytical strategy for biosimilars in a shifting regulatory landscape

Early phase analytical strategy for biosimilars in a shifting regulatory landscape

As FDA and EMA guidance continues to reinforce analytical comparability as the foundation of biosimilar development, investing in comprehensive early-stage characterisation is becoming essential to reduce uncertainty and improve development outcomes, says Dr Andrew J. Reason, CEO at BioPharmaSpec
Manufacturing
Vacuubrand Vario® chemistry diaphragm pumps

Vacuubrand Vario® chemistry diaphragm pumps

The ideal solution for your laboratory
Regulatory
AI in pharma: Practical use cases transforming research, regulatory and medical affairs

AI in pharma: Practical use cases transforming research, regulatory and medical affairs

AI and digital transformation expert Sarah Chan explores the rapidly expanding role of artificial intelligence across the pharmaceutical value chain
Subscribe now